Bionomics is a clinical stage biopharmaceutical company leveraging its proprietary ionX and Multicore platforms to deliver a pipeline of novel drug candidates in central nervous system (CNS) disorders and cancer. Based in Adelaide, Australia, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • BNO Prepares BNC210 for Start of Phase 2 Acute SAD Trial

    20 September 2021

    Download PDF

  • Correction to Appendix 4E

    31 August 2021

    Download PDF

  • Preliminary Final Report FY2021 App 4E and Announcement

    25 August 2021

    Download PDF


Latest Analyst Report